Peter Pertel

2.5k total citations
38 papers, 1.8k citations indexed

About

Peter Pertel is a scholar working on Epidemiology, Infectious Diseases and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Peter Pertel has authored 38 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Epidemiology, 11 papers in Infectious Diseases and 7 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Peter Pertel's work include Cytomegalovirus and herpesvirus research (6 papers), Antimicrobial Resistance in Staphylococcus (5 papers) and Bacterial Identification and Susceptibility Testing (5 papers). Peter Pertel is often cited by papers focused on Cytomegalovirus and herpesvirus research (6 papers), Antimicrobial Resistance in Staphylococcus (5 papers) and Bacterial Identification and Susceptibility Testing (5 papers). Peter Pertel collaborates with scholars based in United States, Switzerland and United Kingdom. Peter Pertel's co-authors include Patricia G. Spear, Joan S. Chmiel, Robert L. Murphy, James Song, John Phair, Linda Poggensee, Robert E. Hirschtick, Daniel Haverstock, Baldur Magnusson and Thierry T. Diagana and has published in prestigious journals such as New England Journal of Medicine, Annals of Internal Medicine and Clinical Infectious Diseases.

In The Last Decade

Peter Pertel

37 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Pertel United States	23	969	493	409	190	188	38	1.8k
Laura Milazzo Italy	23	752 0.8×	679 1.4×	209 0.5×	182 1.0×	155 0.8×	75	2.0k
James Riddell United States	25	707 0.7×	707 1.4×	157 0.4×	146 0.8×	436 2.3×	72	1.9k
Bruce Polsky United States	28	1.4k 1.4×	784 1.6×	166 0.4×	83 0.4×	436 2.3×	78	2.9k
David F. Busch United States	16	1.2k 1.2×	417 0.8×	135 0.3×	167 0.9×	193 1.0×	24	1.5k
Peter Phillips Canada	30	1.5k 1.6×	1.4k 2.9×	151 0.4×	63 0.3×	144 0.8×	76	2.3k
Florence Morfin France	30	1.8k 1.9×	969 2.0×	151 0.4×	51 0.3×	197 1.0×	83	2.8k
Alexander Imhof Switzerland	22	955 1.0×	1.3k 2.6×	68 0.2×	100 0.5×	85 0.5×	38	2.1k
Hee‐Chang Jang South Korea	27	851 0.9×	1.5k 3.1×	287 0.7×	40 0.2×	55 0.3×	119	2.6k
Joel N. Kuritsky United States	18	527 0.5×	562 1.1×	548 1.3×	175 0.9×	54 0.3×	41	1.8k
Mark Shelton United States	23	1.8k 1.9×	1.3k 2.6×	153 0.4×	34 0.2×	245 1.3×	63	2.7k

Countries citing papers authored by Peter Pertel

Since Specialization

Citations

This map shows the geographic impact of Peter Pertel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Pertel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Pertel more than expected).

Fields of papers citing papers by Peter Pertel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Pertel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Pertel. The network helps show where Peter Pertel may publish in the future.

Co-authorship network of co-authors of Peter Pertel

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Pertel. A scholar is included among the top collaborators of Peter Pertel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Pertel. Peter Pertel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gauvreau, Gail M., Jens M. Hohlfeld, J. Mark FitzGerald, et al.. (2023). Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma. European Respiratory Journal. 61(3). 2201193–2201193. 40 indexed citations

Baraliakos, Xenofon, Mikkel Østergaard, Denis Poddubnyy, et al.. (2023). OP0059 EFFECT OF SECUKINUMAB VERSUS ADALIMUMAB BIOSIMILAR ON RADIOGRAPHIC PROGRESSION IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: A RANDOMISED PHASE IIIB STUDY. Annals of the Rheumatic Diseases. 82. 38–40. 4 indexed citations

Gauvreau, Gail M., Jens M. Hohlfeld, Sarah Schmidt Grant, et al.. (2020). Efficacy and Safety of an Inhaled Anti-TSLP Antibody Fragment in Adults with Mild Atopic Asthma. A4207–A4207. 17 indexed citations

Laan, Jan Willem van der, Charles Benson, Solange Corriol‐Rohou, et al.. (2020). Shared Learnings on the New EMA First-in-Human and Early Clinical Trial Guideline: Proceedings From a DIAlogue Session at DIA Europe 2018. Therapeutic Innovation & Regulatory Science. 54(2). 462–467.

Kublin, James G., Sean C. Murphy, Janine Maenza, et al.. (2020). Safety, Pharmacokinetics, and Causal Prophylactic Efficacy of KAF156 in a Plasmodium falciparum Human Infection Study. Clinical Infectious Diseases. 73(7). e2407–e2414. 16 indexed citations

White, Nicholas J., Tran Thanh Duong, Chirapong Uthaisin, et al.. (2016). Antimalarial Activity of KAF156 in Falciparum and Vivax Malaria. New England Journal of Medicine. 375(12). 1152–1160. 71 indexed citations

Dole, Kiran, Adam L. Feire, Baldur Magnusson, et al.. (2016). A First-in-Human Study To Assess the Safety and Pharmacokinetics of Monoclonal Antibodies against Human Cytomegalovirus in Healthy Volunteers. Antimicrobial Agents and Chemotherapy. 60(5). 2881–2887. 22 indexed citations

Pertel, Peter, et al.. (2009). The efficacy and safety of daptomycin vs. vancomycin for the treatment of cellulitis and erysipelas. International Journal of Clinical Practice. 63(3). 368–375. 45 indexed citations

Amakye, Dereck D., Wen Dai, Cynthia J. Girman, et al.. (2009). The Value, Qualification, and Regulatory Use of Surrogate End Points in Drug Development. Clinical Pharmacology & Therapeutics. 86(1). 32–43. 41 indexed citations

10.

Davey, Richard T., Peter Pertel, Alice Benson, et al.. (2008). Safety, Tolerability, Pharmacokinetics, and Efficacy of an Interleukin-2 Agonist Among HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy. Journal of Interferon & Cytokine Research. 28(2). 89–100. 5 indexed citations

11.

Pertel, Peter, Patricia Bernardo, Charles Fogarty, et al.. (2008). Effects of Prior Effective Therapy on the Efficacy of Daptomycin and Ceftriaxone for the Treatment of Community‐Acquired Pneumonia. Clinical Infectious Diseases. 46(8). 1142–1151. 106 indexed citations

12.

Schaeffer, Anthony J., Francesco Montorsi, Vincenzo Scattoni, et al.. (2007). Comparison of a 3‐day with a 1‐day regimen of an extended‐release formulation of ciprofloxacin as antimicrobial prophylaxis for patients undergoing transrectal needle biopsy of the prostate. British Journal of Urology. 100(1). 51–57. 47 indexed citations

13.

Johnson, Patricia A., Jeffrey Adelglass, Bruce Rankin, et al.. (2007). Acute bacterial maxillary sinusitis: time to symptom resolution and return to normal activities with moxifloxacin. International Journal of Clinical Practice. 62(9). 1366–1372. 3 indexed citations

14.

Saltzstein, Daniel R., et al.. (2007). Complicated Urinary Tract Infections Treated with Extended-Release Ciprofloxacin with Emphasis onPseudomonas aeruginosa. Journal of Chemotherapy. 19(6). 694–702. 4 indexed citations

15.

Pertel, Peter & Daniel Haverstock. (2006). Risk factors for a poor outcome after therapy for acute pyelonephritis. British Journal of Urology. 98(1). 141–147. 34 indexed citations

16.

Giordano, Philip, et al.. (2005). Sequential intravenous/oral moxifloxacin versus intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infection. International Journal of Antimicrobial Agents. 26(5). 357–365. 59 indexed citations

17.

Till, Michele, Richard L. Wixson, & Peter Pertel. (2002). Linezolid Treatment for Osteomyelitis Due to Vancomycin‐ResistantEnterococcus faecium. Clinical Infectious Diseases. 34(10). 1412–1414. 34 indexed citations

18.

Pertel, Peter, et al.. (2001). Cell Fusion Induced by Herpes Simplex Virus Glycoproteins gB, gD, and gH-gL Requires a gD Receptor but Not Necessarily Heparan Sulfate. Virology. 279(1). 313–324. 245 indexed citations

19.

Pertel, Peter, Patricia G. Spear, & Richard Longnecker. (1998). Human Herpesvirus-8 Glycoprotein B Interacts with Epstein–Barr Virus (EBV) Glycoprotein 110 but Fails to Complement the Infectivity of EBV Mutants. Virology. 251(2). 402–413. 20 indexed citations

20.

Pertel, Peter & Patricia G. Spear. (1996). Modified Entry and Syncytium Formation by Herpes Simplex Virus Type 1 Mutants Selected for Resistance to Heparin Inhibition. Virology. 226(1). 22–33. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact